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Abstract
Background: Peer support can enable patient engagement with healthcare services, particularly for marginalised
populations. In this randomised controlled trial, the efficacy of a peer support intervention at promoting successful
engagement with clinical services for chronic hepatitis C was assessed.
Methods: In London, UK, potential participants were approached through outreach services for problematic drug
use and homelessness. Individuals positive for hepatitis C virus (HCV) after confirmatory testing were randomised
using an online service to the intervention (peer support) or standard of care. The primary outcome of interest was
successful engagement with clinical hepatitis services. The study was non-blinded. Absolute differences were
calculated using a generalised linear model and the results compared to logistic regression.
Results: Three hundred sixty-four individuals consented to participate. One hundred one had chronic hepatitis C
and were randomised, 63 to receive the intervention (peer support). A successful outcome was achieved by 23
individuals in this arm (36.5%) and seven (18.4%) receiving the standard of care, giving an absolute increase of
18.1% (95% confidence interval 1.0–35.2%, p value = 0.04). This was mirrored in the logistic regression (odds ratio
2.55 (0.97–6.70), p = 0.06). No serious adverse events were reported.
Conclusions: Peer support can improve the engagement of patients with chronic HCV with healthcare services.
Trial registration: ISRCTN24707359. Registered 19th October 2012.
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Background
In England, around 160,000 individuals were estimated to
be chronically infected with hepatitis C virus (HCV) in
2017, a large proportion of whom are from underserved
and marginalised groups [1]. The UK has committed to
eliminating HCV by 2025 [2]; thus, it is critical that all
population groups are able to access effective diagnostic
and treatment services.
Underserved and vulnerable groups are defined by
factors that render engagement with normal healthcare
services and pathways problematic, which often results
in them being labelled as ‘hard-to-reach’ by such
systems. They include homeless persons, people who
inject drugs and ex-prisoners. These groups can be vul-
nerable to a range of infectious diseases due to living
conditions, exposure to injecting drug use, alcoholism,
generally poor physical and mental health and socio-
structural factors that criminalise, isolate and stigmatise.
Exposure to, and prevalence of, hepatitis B virus (HBV)
and HCV among marginalised groups in the UK is
known to be high [3–5]. Whilst testing for HCV and
HBV is not uncommonly offered by UK outreach ser-
vices, this is not sufficient to promote effective engage-
ment through the full diagnostic and treatment
process.
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The treatment landscape for chronic HCV has been
revolutionised in the past decade, with the licencing of a
series of directly acting antivirals (DAAs) for HCV [6].
Although expensive, these drugs have radically improved
the patient treatment experience, shortened the duration
of therapy, reduced the likelihood of adverse events and
have better (pan-genotype) treatment success rates. Such
regimens offer hope to all chronically infected indi-
viduals, but most especially those who may struggle to
access specialist services and adhere to treatment.
Monthly treatment targets of chronic HCV patients
have been set for each Operational Delivery Network
(ODN) in England; as hospitals work through their lists
of patients awaiting DAAs, greater efforts will be
needed to reach the individuals less likely to engage [7].
This includes those currently injecting drugs, a key
population if elimination of HCV is to be achieved.
Underserved and vulnerable groups as a whole will act
as a reservoir of infection if their healthcare needs are
not addressed.
Peer support is a mechanism to enable active engage-
ment with healthcare among marginalised groups. Peers
have personal experience of a specific illness or lifestyle
that enables them to support others experiencing similar
challenges [8]. Peer support has been used worldwide,
particularly in mental health, to remove barriers to
accessing services, facilitate patient wellbeing and pro-
mote positive clinical outcomes [8]. In chronic hepatitis
C, peers have been documented as playing a wide range
of roles [9–11]; helping individuals to engage with their
treatment is a particularly critical area [12, 13]. Qualita-
tive and observational studies have highlighted peer
support models as valuable in the care of chronically
infected HCV patients in Australia, Georgia, the UK and
the USA [12–25], but quantitative trial data is lacking.
Peer support has been deemed one of ten priorities to
improve access to HCV treatment for people who inject
drugs in low- and middle-income countries [26].
Given the promising observational data and qualitative
evidence, and the absence of quantitative trial data on
the value of peer support for promoting successful
engagement with clinical services for chronic HCV, we
conducted a randomised controlled trial (RCT) aimed to
evaluate the efficacy of an individual-level peer support
intervention.
Methods
Study design
This was a randomised non-blinded controlled trial in
London, UK, to assess the efficacy of a community-con-
trolled, individual-level, peer support intervention to pro-
mote engagement with healthcare services in individuals
chronically infected with HCV.
Participants
Potential participants were approached at outreach ser-
vices for problematic drug use and homelessness for
point-of-care HCV, HBV, and HIV testing. Inclusion
criteria were being marginalised by normal healthcare
services (evidenced by engagement with outreach services
as a client), over the age of 16 years, and willing and able
to provide written informed consent. Potential par-
ticipants were excluded if they were already on treatment
for HCV or HBV. Additionally, individuals known by out-
reach services to be positive for HCV and/or HBV who
were not on treatment (‘known positives’) were approached.
Testing procedures
All consenting participants were asked to complete a
baseline questionnaire (Additional file 1) by the study Re-
search Nurses, which collected self-reported demographic,
medical and contact information. They were offered
point-of-care testing for HCV (OraQuick anti-HCV),
HBV (nal von Minden HBsAg) and HIV (Alere third
generation). Participants could choose to have less than
the full complement of tests.
Participants found to be point-of-care test positive for
HCV or HBV were informed at the time of screening
and had venous and/or dried blood spot samples of
blood taken for confirmatory testing by Public Health
England (PHE), which provides a national reference ser-
vice for HCV and HBV testing. Confirmatory antibody
testing for chronic infection was undertaken for HCV
and antigen/antibody testing for HBV; if positive, this
was followed by polymerase chain reaction (PCR) testing
for genetic material and genotyping. Individuals positive
for HIV at the point-of-care testing stage were informed
and the results provided to their primary care practi-
tioner, if permission was given.
Anyone testing positive for HCV or HBV at this con-
firmatory stage was fully enrolled into the trial and
randomised to the intervention or standard care arms.
Randomisation and masking
Randomisation was undertaken centrally by the research
nurses using the web-based Sealed Envelope system. Eli-
gible enrolled participants were randomised 1:2 standard of
care to intervention arm. Additional details are presented
in Additional file 2, including the sample size calculation.
Standard of care
Enrolled participants not randomised to the intervention
arm were referred to one of four hospitals (The Royal
London/Barts Health, King’s College London, Royal
Free, University College). Their test results—and noti-
fication of their study participation—were sent to their
primary care practitioner, if permission was given. Indi-
viduals were allowed to choose which hospital to be
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referred to, regardless of their study arm. There was no
further intervention by the trial team. The specific site
of referral for both arms of the study was chosen based
on participant preference and geographical location
prior to randomisation results being known. Referral
sites did not explicitly know the randomisation status of
the patients.
Intervention
In our community-controlled model of peer support,
participants in the intervention arm were individually
assigned to a peer advocate from the London-based
homeless charity and advocacy organisation Ground-
swell. The details of the development of this intervention
are presented in Additional file 2.
Outcomes and follow-up
The primary outcome of interest was successful achieve-
ment of an appropriate clinical endpoint, defined as en-
gagement with clinical hepatitis services i.e. three
engagements within 6 months of the first booked clinical
appointment. An engagement could be a review with a
doctor or nurse, FibroScan or ultrasound scan, or a
blood test. This number was set after consultation with
clinical colleagues to demonstrate a real willingness of
the participant to engage.
The secondary trial outcomes for enrolled participants
were (a) successfully reaching a sustained virological re-
sponse (SVR; an undetectable viral load for 6 months
after the end of treatment) against HCV and (b) success-
ful engagement, reaching a full clinical diagnosis, or
commencing treatment for HBV.
Outcome data collection and the process for with-
drawals are described in more detail in Additional file 2.
Statistical analysis
Data collection and cleaning are described in detail in
Additional file 2.
Following descriptive analyses of the baseline popula-
tion, absolute differences in the proportion of parti-
cipants successfully achieving three engagements in the
intervention and control arms were calculated as an
intention-to-treat analysis using a generalised linear
model assuming a binomial distribution and an identity
link function. The results of this model were compared
to that of a logistic regression model. Additional details
about the building of these models are presented in
Additional file 2.
After examining the distribution of individuals who
withdrew or became lost to follow-up (LFU), a post hoc
per protocol sensitivity analysis was planned where
people in the intervention arm who withdrew or became
LFU before they had a peer advocate assigned were
re-categorised into the standard of care arm.
Descriptive analyses were undertaken for the secondary
outcomes of interest, due to the small numbers of
relevant patients.
Results
Baseline study population
Between 15 August 2013 and 10 June 2015, 364 indivi-
duals across a total of 27 outreach services in London con-
sented to point-of-care testing (Fig. 1). Recruitment was
stopped when we reached our sample size, allowing for
delays in obtaining confirmatory PCR results. Follow-up
was completed on 29 April 2016. The baseline charac-
teristics of the individuals who consented are presented
in Table 1.
Consenting participants were largely male (278/364,
76.4%), with a median age of 43 years (interquartile
range 35–48), born in the UK (276/364, 75.8%) and of
White other or White central/eastern European ethnicity
(258/364, 76.4%). High levels of key social risk factors
associated with being at risk for HCV infection were dis-
played, including 82/364 (22.5%) of participants being
current injecting users of illicit drugs. The majority of par-
ticipants were active smokers (321/364, 88.2%). Around
three quarters (272/364) had previously been tested for
HCV or HBV and over a third previously diagnosed with
HBV, HCV or another form of liver disease (136/364).
Fifty-four individuals (14.8%) were recruited as ‘known
positives’ from services.
Of these 364 individuals, 136 had a positive point-
of-care test for HCV, three for HBV and three for HIV.
Chronic HBV infection was confirmed in one individual
by PCR testing, who was enrolled and placed in the
intervention arm. One hundred one individuals were
enrolled with a chronic HCV infection by PCR. This
population was similar to the overall study population,
but a greater proportion of individuals were from a
White other ethnic background (70/101, 69.3%), current
users of illicit drugs (79/101, 78.2% versus 213/364,
58.5%) or displayers of other social risk factors; had
been previously tested or diagnosed; or were ‘known
positives’ (54/101, 53.5% versus 54/364, 14.8%).
Sixty-three individuals were randomised to receive the
intervention and 38 to the standard of care arm (Fig. 1).
The distribution of baseline characteristics was not
found to be appreciably different between randomisation
arms among the 101 individuals positive for a chronic
HCV infection who were enrolled (Table 1).
Withdrawals and losses to follow-up
Three individuals withdrew post-randomisation during
the study, one from the standard of care and two from the
intervention arm (Fig. 1). The characteristics of those who
withdrew were not substantially different from those who
did not (Additional file 3). Fifty-nine individuals were
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LFU, three of whom were in the intervention arm and
whom became LFU before a peer advocate was assigned
(Fig. 1). Their characteristics were not substantially diffe-
rent from the overall enrolled population, apart from
when it came to a history of imprisonment: more had
been imprisoned in the last 5 years (Additional file 3).
Successful engagement with clinical services
50.5% of the HCV-positive individuals (51/101) engaged
with services at least once within 6 months of their first
booked clinical appointment (median one, maximum
six, interquartile range 0–3). 29.7% (30/101) achieved a
successful outcome, i.e. engaged with services three
times or more. Of these 30 individuals, seven were in
the standard of care arm (7/38, 18.4%) and 23 (23/63,
36.5%) were in the intervention arm. Their baseline
characteristics are documented in Table 2.
Outcomes by peer advocate were investigated as part of
the process to determine the potential need to adjust for
clustering during the regression analysis. Of the 63 individ-
uals in the intervention arm, five were not assigned a peer
advocate, two due to withdrawing and three due to becom-
ing LFU before assignment could occur. Of the remaining
58 individuals, peer advocate A was assigned to the greatest
number (33/58, 56.9%; Additional file 4). Although there
was variation in terms of the proportions of individuals
cared for by each peer advocate that reached a
successful outcome, the confidence intervals (CIs)
around each percentage overlapped with the overall
percentage.
Univariable regression models were thus built without
adjustment for clustering by peer advocate to examine
the relationship between the intervention and success-
fully engaging. In the model of absolute differences,
patients in the intervention arm were found to have an
18.1% (95% CI 1.0%–35.2%, p value = 0.04) increased like-
lihood of a successful treatment outcome versus those in
the standard of care arm. In the model of relative diffe-
rences, the odds of reaching a successful treatment out-
come were 2.55 times higher (95% CI 0.97–6.70, p = 0.06)
among individuals in the intervention arm versus those in
the standard of care arm.
Although imbalances by randomisation arm had not
been detected in baseline characteristics, bivariable
models adjusting for potential confounders were created.
Point estimates differed (Additional file 5), but the CIs
for each model overlapped with that of the univariable
model for both absolute and relative measures. A
Lowess plot of age versus outcomes revealed a non-
linear relationship and thus both age and age squared
were included in the relevant model. Imprisonment
and sex had particularly large impacts in terms of
drawing the CIs towards the null. Smoking and HIV
status were collinear with the outcome and thus could
not be assessed.
364 individuals PoC tested
136 HCV or HBV PoC
positive
(2 HIV PoC positive also 
HCV PoC positive)
101 HCV PCR positive 1 HBV PCR positive
227 PoC negative/not 
done/borderline/test failed 
for HCV, HBV and HIV
1 in intervention armRandomisation
63 in intervention arm38 in standard of care arm
34 HCV and/or HBV PCR 
negative, not done or test 
failed
4 Site A
21 Site B
8 Site C
5 Site D
8 Site A
34 Site B
9 Site C
10 Site D
2 withdrew before referral and peer assigned
7 3+ engagements†
30 <3 engagements^
23 3+ engagements‡
35 <3 engagements*
having had at least one appointment (4 Site B)
^ 18 LFU before first appointment (11 Site B, 5 Site C, 2 Site D); 4 LFU having had at least one appointment (1 Site B, 1 Site C, 2 Site D); 3 LFU to study but 
not to hospital (2 Site A, 1 Site B)
LFU having had at least one appointment (2 Site B, 1 Site C)
* 21 LFU before first appointment (3 Site A, 11 Site B, 3 Site C, 4 Site D); 3 LFU having had at least one appointment (3 Site B)
1 HIV PoC positive, HCV 
and HBV PoC negative
3 LFU before peer assigned (1 Site A, 1 Site B, 1 Site D)
Fig. 1 Flow chart of participation
Stagg et al. BMC Medicine           (2019) 17:71 Page 4 of 9
Table 1 Baseline characteristics of consenting participants
Characteristic Overall Enrolled^ Intervention^
No. Col. % No. Col. % No. Col. % p
Overall 364 100.0 101 100.0 63 100.0
Sex 0.45
Male 278 76.4 81 80.2 52 82.5
Female 86 23.6 20 19.8 11 17.5
Missing 0 0.0 0 0.0 0 0.0
Age categorised (years) 0.58
16–25 22 6.0 1 1.0 1 1.6
26–35 79 21.7 16 15.8 10 15.9
36–45 130 35.7 42 41.6 23 36.5
46–55 105 28.8 35 34.7 25 39.7
56–65 27 7.4 6 5.9 3 4.8
66–75 1 0.3 1 1.0 1 1.6
Missing 0 0.0 0 0.0 0 0.0
Ethnicity 0.59
White other 173 47.5 70 69.3 42 66.7
White central/eastern European 85 23.4 9 8.9 6 9.5
Indian subcontinent 5 1.4 1 1.0 0 0.0
Black 72 19.8 12 11.9 9 14.3
Mixed/other 27 7.4 8 7.9 6 9.5
Missing 2 0.5 1 1.0 0 0.0
UK born > 0.99
No 88 24.2 23 22.8 14 22.2
Yes 276 75.8 78 77.2 49 77.8
Missing 0 0.0 0 0.0 0 0.0
Use of illicit drugs 0.56
Absent 69 19.0 1 1.0 1 1.6
Present, but unknown what/when 1 0.3 21 20.8 14 22.2
Present, previous 81 22.3 0 0.0 0 0.0
Present, current non-injecting 131 36.0 47 46.5 26 41.3
Present, current injecting 82 22.5 32 31.7 22 34.9
Missing 0 0.0 0 0.0 0 0.0
Homelessness 0.92
Absent 51 14.0 15 14.9 10 15.9
Present, previous 112 30.8 51 50.5 32 50.8
Present, current 200 54.9 35 34.7 21 33.3
Missing 1 0.3 0 0.0 0 0.0
Imprisonment 0.34
Absent 128 35.2 16 15.8 10 15.9
Present, > 5 years ago 103 28.3 47 46.5 33 52.4
Present, ≤ 5 years ago 132 36.3 37 36.6 20 31.7
Missing 1 0.3 1 1.0 0 0.0
Alcohol-related concerns 0.68
Absent, not sure or missing 148 40.7 45 44.6 27 42.9
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There was no evidence of effect modification by any of
the predefined variables. Tests for interaction failed for
ethnicity, being UK born, use of illicit drugs and previ-
ous testing due to small numbers in particular strata.
Sensitivity analyses
Ad hoc per protocol analyses were undertaken for
both the absolute and relative models to determine
the impact of initial non-assignation of a peer ad-
vocate to individuals in the intervention arm due to
withdrawal or LFU. Assigning affected individuals to
the standard of care arm, the absolute difference in
the percentage likelihood of achieving a successful
treatment outcome increased to 23.4% (95% CI 6.6–
40.1%, p = 0.01) and the relative difference to 3.38
(95% CI 1.29–8.88, p = 0.01).
Table 1 Baseline characteristics of consenting participants (Continued)
Characteristic Overall Enrolled^ Intervention^
No. Col. % No. Col. % No. Col. % p
Present 216 59.3 56 55.4 36 57.1
Smoking –*
Current 321 88.2 100 99.0 62 98.4
Ex-smoker 14 3.8 0 0.0 0 0.0
Missing 29 8.0 1 1.0 1 1.6
HIV status > 0.99
Negative or not sure 360 98.9 99 98.0 62 98.4
Positive 4 1.1 2 2.0 1 1.6
HBV vaccination status 0.81
Not vaccinated or not sure 137 37.6 24 23.8 16 25.4
One or more doses 227 62.4 77 76.2 47 74.6
Previous testing 0.29
Not tested or not sure 92 25.3 4 4.0 4 6.3
Yes, for HBV or HCV 272 74.7 97 96.0 59 93.7
Previous diagnosis 0.79
Not diagnosed or not sure 228 62.6 19 18.8 11 17.5
Yes, for HBV, HCV or liver disease 136 37.4 82 81.2 52 82.5
‘Known positive’ at the time of recruitment 0.54
No 310 85.2 47 46.5 31 49.2
Yes 54 14.8 54 53.5 32 50.8
HCV point-of-care test result
Negative 224 61.5
Positive 136 37.4
Not done (refused) 3 0.8
Borderline 1 0.3
HBV point-of-care test result
Negative 306 84.1
Positive 3 0.8
Not done (refused) 46 12.6
Test failed 9 2.5
HIV point-of-care test result
Negative 334 91.8
Positive 3 0.8
Not done (refused) 27 7.4
^Excluding one individual positive for HBV but not HCV at confirmatory testing. *Everyone in both randomisation arms with information available was a current
smoker. Col column, HBV hepatitis B virus, HCV hepatitis C virus, p Fisher’s exact test p value (missing values excluded) comparing individuals in the intervention
and standard of care arms
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Secondary outcomes
Among individuals with a chronic HCV infection, none
achieved a SVR during the study period. The individual
diagnosed with chronic HBV assigned to the interven-
tion arm did not achieve a successful outcome of three
or more engagements with healthcare services within six
months; they became LFU eight months after their first
appointment (with no subsequent appointments).
Adverse events
No serious adverse events were documented within
the study.
Discussion
In a RCT of an individual-level, community-controlled,
peer support intervention to promote successful engage-
ment with clinical services for individuals diagnosed
with chronic HCV, we demonstrate that providing
patients with a peer advocate increased their absolute like-
lihood of successfully engaging with healthcare systems by
Table 2 Outcomes by study arm and baseline characteristics
Characteristic ≥ 3 engagements
No. Row %
Overall 30 29.7
Randomisation
Standard of care 7 18.4
Intervention 23 36.5
Sex
Male 28 34.6
Female 2 10.0
Missing 0 –
Age categorised (years)
16–25 0 0.0
26–35 3 18.8
36–45 12 28.6
46–55 15 42.9
56–65 0 0.0
66–75 0 0.0
Missing 0 –
Ethnicity
White other 18 25.7
White central/eastern European 1 11.1
Indian subcontinent 0 0.0
Black 7 58.3
Mixed/other 3 37.5
Missing 0 0.0
UK born
No 5 21.7
Yes 25 32.1
Missing 0 –
Use of illicit drugs
Absent 0 0.0
Present, but unknown what/when 3 14.3
Present, previous 0 –
Present, current non-injecting 16 34.0
Present, current injecting 11 34.4
Missing 0 –
Homelessness
Absent 7 46.7
Present, previous 15 29.4
Present, current 0 0.0
Missing 8 –
Imprisonment
Absent 3 18.8
Present, > 5 years ago 18 38.3
Present, ≤ 5 years ago 9 24.3
Table 2 Outcomes by study arm and baseline characteristics
(Continued)
Characteristic ≥ 3 engagements
No. Row %
Missing 0 0.0
Alcohol-related concerns
Absent, not sure or missing 14 31.1
Present 16 28.6
Smoking
Current 30 30.0
Ex-smoker 0 –
Missing 0 0.0
HIV status
Negative or not sure 30 30.3
Positive 0 0.0
HBV vaccination status
Not vaccinated or not sure 8 33.3
One or more doses 22 28.6
Previous testing
Not tested or not sure 1 25.0
Yes, for HBV or HCV 29 29.9
Previous diagnosis
Not diagnosed or not sure 5 26.3
Yes, for HBV, HCV or liver disease 25 30.5
‘Known positive’ at the time of recruitment
No 11 23.4
Yes 19 35.2
Excluding one individual positive for HBV but not HCV at confirmatory testing.
HBV hepatitis B virus, HCV hepatitis C virus
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18.1%. In a logistic regression model, this translated into
2.55 times the odds of a successful outcome, albeit with a
CI that minimally crossed the null.
Importantly, an ad hoc per protocol sensitivity analysis
revealed the impact of not staying within the study for
long enough to be assigned a peer advocate. Within this
population, arrest and imprisonment were key reasons
for becoming LFU. When individuals in the intervention
arm who were never assigned a peer advocate were
analysed as though they were in the standard of care
arm both effect sizes and statistical measures of asso-
ciation were strengthened.
We believe this to be the first RCT to evaluate the effi-
cacy of a peer support intervention at improving engage-
ment with healthcare services for chronic HCV. The
closest previous study found in the literature was a
randomised pilot trial in Belgium of an educational
intervention that included a peer component and use of
FibroScan screening [27]. This study was small (52 par-
ticipants) and did not detect an enduring change in
willingness to be treated in the intervention versus con-
trol arms. A number of descriptive observational studies
have documented the role of different peer models in
HCV testing and treatment [17, 19, 22–25], but provided
no formal proof of the causal effects of the implemented
interventions.
Some limitations of the study should be considered.
The study was not blinded, meaning that participants
were aware of the trial arm that they were assigned to,
as were study staff. This could have altered participant
behaviour and the way that the outcome was docu-
mented during data collection, biasing the effect esti-
mate away from the null, although data collection was
undertaken using standardised forms and processes
across all patients. Data were only collected from the
hospitals that the patients initially chose to attend. It is
possible that patients in the standard of care arm in
particular changed hospital during their engagement
with services, biasing the effect estimate away from the
null. Given that such patients would have likely had to
re-start their diagnostic process from scratch, however,
this can still be seen as a failure within the clinical sys-
tem. Originally, only three peer advocates were planned
to be involved in the intervention arm, but eight were
actually utilised. As we found no evidence of clustering
by peer, this is unlikely to have reduced study power.
Our peer advocates were all male, but we found no
evidence for effect modification by participant sex within
our analysis. No patients achieved a SVR during the
study, partly due to delays placing individuals on treat-
ment as a result of changes in the regimens that were
available within national healthcare services during the
RCT. During the trial, treatment was additionally limited
to those with higher FibroScan scores. This prevented us
from analysing the impact of peer support on treatment
success rates.
Since 2016, ODNs have been responsible for delivering
HCV treatment in England, with monthly treatment
targets that should promote access to DAAs for margi-
nalised individuals. This expansion of treatment comes
with its own challenges regarding ensuring patient
engagement with the diagnostic and treatment pathway.
This study provides high-quality evidence that peer
advocates may provide an efficacious way of promoting
this, in line with global calls for the use of peer support
models in chronic HCV [26].
Conclusions
In conclusion, our findings indicate that peer support
can improve the engagement of patients with chronic
HCV with healthcare services. The cost-effectiveness of
such interventions in the relevant populations should be
assessed before they are implemented in different health-
care settings.
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